1. Home
  2. PODD vs CYBR Comparison

PODD vs CYBR Comparison

Compare PODD & CYBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PODD
  • CYBR
  • Stock Information
  • Founded
  • PODD 2000
  • CYBR 1999
  • Country
  • PODD United States
  • CYBR Israel
  • Employees
  • PODD N/A
  • CYBR N/A
  • Industry
  • PODD Medical/Dental Instruments
  • CYBR Computer Software: Prepackaged Software
  • Sector
  • PODD Health Care
  • CYBR Technology
  • Exchange
  • PODD Nasdaq
  • CYBR Nasdaq
  • Market Cap
  • PODD 22.1B
  • CYBR 24.0B
  • IPO Year
  • PODD 2007
  • CYBR 2014
  • Fundamental
  • Price
  • PODD $311.95
  • CYBR $516.47
  • Analyst Decision
  • PODD Strong Buy
  • CYBR Buy
  • Analyst Count
  • PODD 19
  • CYBR 32
  • Target Price
  • PODD $338.79
  • CYBR $446.48
  • AVG Volume (30 Days)
  • PODD 461.0K
  • CYBR 532.6K
  • Earning Date
  • PODD 11-06-2025
  • CYBR 11-06-2025
  • Dividend Yield
  • PODD N/A
  • CYBR N/A
  • EPS Growth
  • PODD N/A
  • CYBR N/A
  • EPS
  • PODD 3.32
  • CYBR N/A
  • Revenue
  • PODD $2,359,500,000.00
  • CYBR $1,200,117,000.00
  • Revenue This Year
  • PODD $29.27
  • CYBR $35.70
  • Revenue Next Year
  • PODD $18.30
  • CYBR $19.22
  • P/E Ratio
  • PODD $95.15
  • CYBR N/A
  • Revenue Growth
  • PODD 26.00
  • CYBR 39.45
  • 52 Week Low
  • PODD $227.03
  • CYBR $271.68
  • 52 Week High
  • PODD $353.50
  • CYBR $526.19
  • Technical
  • Relative Strength Index (RSI)
  • PODD 41.83
  • CYBR 62.40
  • Support Level
  • PODD $320.76
  • CYBR $510.99
  • Resistance Level
  • PODD $326.81
  • CYBR $525.81
  • Average True Range (ATR)
  • PODD 7.35
  • CYBR 8.70
  • MACD
  • PODD -0.26
  • CYBR 0.45
  • Stochastic Oscillator
  • PODD 1.89
  • CYBR 78.71

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

About CYBR CyberArk Software Ltd.

CyberArk is a cybersecurity vendor focused on the identity market. The company's core privileged access management offering is a market leader in that subsegment, with more than half of the Fortune 500 as CyberArk customers. The identity security vendor was founded in 1999 and has around 9,000 customers across various industries. While CyberArk historically sold its security solutions primarily via on-premises licenses, over the past few years it has transitioned to a subscription recurring-revenue model.

Share on Social Networks: